611 Gateway Boulevard
Suite 120
South San Francisco, CA 94080
United States
650 484 0886
https://graphitebio.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 6
As of March 21, 2024, Graphite Bio, Inc. was acquired by LENZ Therapeutics, Inc., in a reverse merger transaction. Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. The company offers GPH102 for the treatment of beta-thalassemia; and GPH201 for the treatment of XSCID, a life-threatening disease for multiple mutations in a single gene. It also offers GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is based in South San Francisco, California.
Graphite Bio, Inc.’s ISS governance QualityScore as of 1 March 2024 is 7. The pillar scores are Audit: 8; Board: 5; Shareholder rights: 8; Compensation: 9.